TriangleDISEASE & TREATMENT SETTING
OPDIVO QVANTIG: advanced Renal cell carcinoma (first-line) after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy.
Broader topic: Renal Cell Cancer
- Source population
- Not part of this definition
- Disease extent
- advanced
- Treatment line
- first-line
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- following treatment with intravenous nivolumab and ipilimumab combination therapy
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for OPDIVO QVANTIG (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy.
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice